Twin Capital Management Inc. Grows Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Twin Capital Management Inc. boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 7.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 32,786 shares of the biopharmaceutical company's stock after buying an additional 2,392 shares during the quarter. Twin Capital Management Inc.'s holdings in Gilead Sciences were worth $3,674,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of GILD. Smallwood Wealth Investment Management LLC purchased a new position in shares of Gilead Sciences during the 1st quarter valued at approximately $25,000. Goodman Advisory Group LLC purchased a new stake in Gilead Sciences in the 1st quarter worth $29,000. Core Alternative Capital increased its holdings in Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 241 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC increased its holdings in Gilead Sciences by 158.8% in the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after acquiring an additional 216 shares in the last quarter. Finally, Investment Research & Advisory Group Inc. increased its holdings in Gilead Sciences by 33.3% in the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 100 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Trading Down 0.5%

Gilead Sciences stock traded down $0.58 during trading on Friday, hitting $108.22. The company had a trading volume of 6,627,889 shares, compared to its average volume of 7,673,118. The stock has a market cap of $134.62 billion, a price-to-earnings ratio of 22.78, a price-to-earnings-growth ratio of 0.70 and a beta of 0.29. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16. Gilead Sciences, Inc. has a 1-year low of $70.78 and a 1-year high of $119.96. The company's 50 day simple moving average is $108.81 and its 200-day simple moving average is $105.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The company's quarterly revenue was down .3% on a year-over-year basis. During the same period last year, the business posted ($1.32) earnings per share. As a group, analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were paid a dividend of $0.79 per share. The ex-dividend date was Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 2.92%. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Morgan Stanley boosted their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price target for the company. Oppenheimer cut their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Finally, JPMorgan Chase & Co. lifted their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Nine equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $111.38.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the business's stock in a transaction dated Tuesday, July 15th. The shares were sold at an average price of $111.03, for a total transaction of $333,090.00. Following the sale, the insider directly owned 117,168 shares in the company, valued at $13,009,163.04. This represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the business's stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $109.74, for a total transaction of $548,700.00. Following the sale, the director owned 8,920 shares in the company, valued at $978,880.80. This trade represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 72,000 shares of company stock valued at $7,844,775 over the last three months. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.